DrHarry Klimis
Senior Research Fellow
Faculty of Medicine and Health
- Senior Research FellowFaculty of Medicine and Health
Research projects & supervision summary
Dr Klimis’ research program focuses on improving cardiovascular outcomes for cancer patients and survivors through integrated care pathways, digital health–enabled prevention strategies, and advanced echocardiographic assessment. He supervises HDR students working across cardio‑oncology, cardiovascular prevention, mobile health interventions, and rapid‑access cardiology models. His projects involve collaboration with WARC, PHRI/McMaster University, and national research networks to support translational, scalable cardiovascular care.
CORIS‑1: Cardio‑Oncology Registry and Case–Control Study
A prospective case–control study and large ongoing registry evaluating cardiovascular risk, biomarkers, imaging markers, and clinical outcomes in cancer patients referred to a cardio‑oncology service. The study compares 300 cancer patients with 300 matched controls and follows a broader registry cohort (target n=4000) to support long‑term risk‑stratification research.
CORIS‑2: Randomised Trial of a Cardio‑Oncology Service Model
A randomised comparative‑effectiveness trial testing whether structured cardio‑oncology clinic follow‑up reduces cancer therapy interruption and improves cardiovascular risk factor control compared with usual care. Outcomes include treatment continuity, cardiotoxicity, and major cardiovascular events.
ICARUS‑TC: Cardiovascular Risk Reduction in Testicular Cancer Survivors
A multi‑centre randomised controlled trial evaluating whether systematic cardiovascular risk‑factor optimisation (lipids, blood pressure, lifestyle) improves prevention outcomes in men receiving or recently treated with cisplatin‑based chemotherapy for testicular cancer.
SENTINEL‑ICI: Surveillance for Early ICI‑Related Cardiotoxicity
A prospective multimodality surveillance study using GLS, LVEF, ECG, and cardiac biomarkers to detect early subclinical cardiotoxicity in patients receiving immune checkpoint inhibitors, with structured follow‑up at 1, 3, 6, and 12 months.
RESEARCH PROJECTS & ACTIVITIES
- RESEARCH-BASED DEGREE SUPERVISIONCardio-oncology in older adults